|Bid||2.7000 x 1100|
|Ask||2.6400 x 1000|
|Day's Range||2.6050 - 2.9700|
|52 Week Range||1.9100 - 11.4270|
|Beta (5Y Monthly)||2.35|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
A New York investment firm has raised $210 million for startups coming out of Boston-based biotech accelerator Xontogeny. It announced its first investment Tuesday: a $17 million early-stage funding of a local rare-disease startup.
Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock. Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018. This means hedge funds […]
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 4) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Bioanalytical ...
Cancer. Research shows nearly every sixth death in the world is due to the disease, making it the second leading cause of death behind cardiovascular diseases. The global pharmaceutical industry is estimated ...
Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 19) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Avid ...
By John Vandermosten, CFA American Gene Technologies (AGT) is a genetic medicines company developing a portfolio of therapies that employ the company’s proprietary lentiviral vector (LV) platform to focus ...
Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.
Big Pharma is rapidly increasing its investments into biotech companies aiming to treat disease by targeting the microbiome. Some are also working on using bacterial strains as drugs.